Genotype and Phenotype of Transthyretin Cardiac Amyloidosis
Mathew S. Maurer(Alnylam Pharmaceuticals (United States)), Claudio Rapezzi(University of Ferrara), D. Eric Steidley(WinnMed), Sanjiv J. Shah(Northwestern University), Ronald Witteles(Alnylam Pharmaceuticals (United States)), Márcia Waddington‐Cruz(Université Paris-Sud), Hector Ventura(Ochsner Health System), Mazen Hanna(Cleveland Clinic), Rajiv Mundayat(Pfizer (United States)), Violaine Planté‐Bordeneuve(Université Paris-Est Créteil), Daniel J. Lenihan(Saint Francis Medical Center), Daniel Jacoby(Baim Institute for Clinical Research), Scott L. Hummel(VA Ann Arbor Healthcare System), Arnt V. Kristen(Heidelberg University), Brian Drachman(Penn Presbyterian Medical Center), Thibaud Damy(Amyloidosis Foundation), Stephen S. Gottlieb(University of Maryland, Baltimore), Martha Grogan(Mayo Clinic in Arizona), Daniel P. Judge(Medical University of South Carolina), Savitri Fedson(Michael E. DeBakey VA Medical Center), Ole B. Suhr(Umeå University), Teresa Coelho(Universidade do Porto), Angela Dispenzieri(Mayo Clinic), Srinivas Murali(Allegheny General Hospital), Marc A. Silver(Banner - University Medical Center Phoenix)
Cited by 540
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
|European Heart Journal|2016|2.5k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k